The convenience of family and community health nurses-led care for the treatment of rheumatic diseases with biological or targeted synthetic disease-modifying antirheumatic drugs. The experience of Valcamonica, Italy

{"OBJECTIVE:":[0],"To":[1],"investigate":[2],"the":[3,14,104,199],"role":[4],"of":[5,18,207],"family":[6],"and":[7,16,20,27,53,73,81,88,114,155,170,216],"community":[8],"health":[9],"nurses":[10],"(FCHNs)":[11],"in":[12,29,127,157,167,172],"monitoring":[13,206],"safety":[15,72],"efficacy":[17,74],"biological":[19],"targeted":[21],"synthetic":[22],"disease-modifying":[23],"antirheumatic":[24],"drugs":[25],"(bDMARDs":[26],"tsDMARDs)":[28],"chronic":[30],"rheumatic":[31],"diseases.":[32],"METHODS:":[33],"We":[34],"followed":[35],"141":[36],"consecutive":[37],"patients":[38,208],"(median":[39],"age":[40],"59":[41],"years;":[42],"69%":[43],"female)":[44],"with":[45,92,119,134],"autoimmune":[46],"diseases,":[47],"mainly":[48],"rheumatoid":[49],"arthritis":[50],"(RA;":[51],"46.1%)":[52],"spondyloarthritis":[54],"(SpA;":[55],"46.8%),":[56],"receiving":[57,209],"bDMARDs":[58,210],"or":[59,97,211],"tsDMARDs":[60,212],"from":[61,121],"January":[62],"2024":[63],"to":[64,103,222],"March":[65],"2025":[66],"(\\"IFER\\"":[67],"protocol).":[68],"FCHNs":[69,156],"monitored":[70],"treatment":[71,107,195],"using":[75],"patient-reported":[76],"outcomes":[77],"every":[78],"2":[79,138],"months":[80],"composite":[82],"disease":[83,95,99,158],"activity":[84,100,159],"indices":[85],"at":[86],"6":[87],"12":[89],"months.":[90],"Patients":[91],"adverse":[93,110,129],"events,":[94,111],"complications,":[96],"high":[98],"were":[101,117],"referred":[102],"rheumatologist":[105],"for":[106],"reassessment.":[108],"Major":[109],"healthcare":[112],"costs,":[113],"rheumatology":[115,186],"visits":[116,187],"compared":[118,133],"data":[120],"2021-2023.":[122],"RESULTS:":[123],"No":[124],"significant":[125],"difference":[126],"major":[128],"events":[130],"was":[131,161],"observed":[132],"previous":[135],"years":[136],"(deaths:":[137],"vs.":[139,143,149,181,191],"3;":[140],"hospitalizations:":[141],"9":[142],"25;":[144],"emergency":[145],"room":[146],"visits:":[147],"3":[148],"12;":[150],"p=ns).":[151],"Agreement":[152],"between":[153],"rheumatologists":[154],"assessment":[160],"moderate":[162],"overall":[163],"(Cohen's":[164],"κ=0.54±0.06),":[165],"good":[166],"RA":[168],"(κ=0.65±0.08),":[169],"poor":[171],"SpA":[173],"(κ=0.29±0.10).":[174],"Per-capita":[175],"annual":[176],"costs":[177],"decreased":[178],"significantly":[179,196],"(€5164":[180],"€4590;":[182],"p<0.001),":[183],"as":[184],"did":[185],"per":[188],"patient/year":[189],"(2.16":[190],"1.67;":[192],"p<0.001).":[193,203],"First-line":[194],"increased":[197],"during":[198],"IFER":[200],"period":[201],"(Log-rank":[202],"CONCLUSIONS:":[204],"FCHN-led":[205],"appears":[213],"feasible,":[214],"safe,":[215],"cost-effective.":[217],"Further":[218],"studies":[219],"are":[220],"warranted":[221],"confirm":[223],"these":[224],"findings.":[225]}